FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Corporation (NASDAQ:BRKR) – Analysts at Zacks Research dropped their FY2025 EPS estimates for shares of Bruker in a report released on Monday, November 24th. Zacks Research analyst Team now expects that the medical research company will post earnings per share of $1.90 for the year, down from their prior estimate of $1.97. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q1 2026 earnings at $0.39 EPS, FY2026 earnings at $2.07 EPS, Q3 2027 earnings at $0.64 EPS and FY2027 earnings at $2.45 EPS.

BRKR has been the topic of several other reports. UBS Group increased their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Citigroup cut their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th. Rothschild Redb upgraded shares of Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. TD Cowen raised their price objective on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a report on Tuesday, November 4th. Finally, Wells Fargo & Company reduced their target price on Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and an average price target of $50.25.

Bruker Trading Down 0.6%

BRKR opened at $49.03 on Wednesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker has a one year low of $28.53 and a one year high of $64.64. The company has a market cap of $7.45 billion, a P/E ratio of 94.29, a PEG ratio of 5.31 and a beta of 1.26. The business’s 50-day simple moving average is $38.60 and its 200-day simple moving average is $37.57.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is -125.00%.

Insider Activity

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares of the company’s stock, valued at $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Several institutional investors have recently bought and sold shares of BRKR. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bruker by 9,800.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,851 shares of the medical research company’s stock worth $158,000 after acquiring an additional 4,802 shares during the period. Armistice Capital LLC acquired a new stake in Bruker in the third quarter valued at about $321,000. Dark Forest Capital Management LP boosted its holdings in Bruker by 256.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 71,779 shares of the medical research company’s stock valued at $2,332,000 after purchasing an additional 51,614 shares in the last quarter. XTX Topco Ltd acquired a new position in Bruker during the 3rd quarter worth approximately $589,000. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Bruker by 408.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 831,834 shares of the medical research company’s stock valued at $27,026,000 after buying an additional 668,078 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.